Voyager Therapeutics, Inc.
VYGR
$4.46
-$0.42-8.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.75% | 157.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.75% | 157.02% | |||
| Cost of Revenue | -6.45% | 14.48% | |||
| Gross Profit | 19.04% | 13.89% | |||
| SG&A Expenses | 1.52% | -22.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.98% | 5.10% | |||
| Operating Income | 13.60% | 16.47% | |||
| Income Before Tax | 1.41% | 16.66% | |||
| Income Tax Expenses | -89.16% | 453.33% | |||
| Earnings from Continuing Operations | 1.67% | 16.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.67% | 16.45% | |||
| EBIT | 13.60% | 16.47% | |||
| EBITDA | 14.43% | 16.59% | |||
| EPS Basic | 1.90% | 16.64% | |||
| Normalized Basic EPS | 14.21% | 16.85% | |||
| EPS Diluted | 0.86% | 16.79% | |||
| Normalized Diluted EPS | 14.21% | 16.85% | |||
| Average Basic Shares Outstanding | 0.23% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||